Marked improvement in survival and muscle function in DyW mouse models, including dose-dependent increases in grip strength and normalization of muscle histology Favorable safety and pharmacodynamic ...
Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for its congenital muscular dystrophy type 1a (LAMA2-CMD) gene therapy. As per ...
TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Modalis) (Tokyo Stock Exchange: 4883) today announced that it has entered into a joint research agreement with JCR ...
Robust, muscle-specific activation of LAMA1 following a single administration of muscle-tropic AAV vectors encoding the GNDM activator Marked improvement in survival and muscle function in DyW mouse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results